Providence cancer research highlighted at ESMO20

Providence cancer research highlighted at ESMO20

Providence Cancer Institute joins oncology professionals around the world for ESMO Virtual Congress 2020, the annual meeting of the European Society for Medical Oncology, held online from September 14 through October 18. The virtual meeting will present promising new developments aimed at improving cancer patient care. 

Several abstracts with contributions by investigators at Earle A. Chiles Research Institute, a division of Providence Cancer Institute, are selected for presentation at the conference.

Lung cancer and early phase immunotherapy research by Rachel E. Sanborn, M.D., associate member and director, Phase I Clinical Trials Program, and co-director, Providence Thoracic Oncology Program, are highlighted in various abstracts, and a pilot study in head and neck cancer features contributions by Rom S. Leidner, M.D., co-director, Providence Head and Neck Cancer Clinic.

View a list of the abstracts below, with links to additional information. 

Proferred Paper Sessions 

Non-Small Cell Lung Cancer (NSCLC) Metastatic 1

Abstract 1258O: Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. B.C. Cho, K.H. Lee, E.K. Cho, D.W. Kim, J.S. Lee, J.Y. Han, S.W. Kim, A. Spira, E. Haura, J. Sabari, R. Sanborn, J. Bauml, J. Gomez, P. Lorenzini, J. Infante, J.

Presented September 20, 2020 at 14:25-16:05 CEST on Channel 1.

Investigational Immunotherapy

Abstract 1020O: A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours. Sharma MR, Sanborn RE, Cote GM, Bendell J, S Kaul, Chen F.

Presented September 20, 2020 at 14:25-16:05 CEST on Channel 2.

Mini Oral Sessions 

Non Small Cell Lung Cancer (NSCLC) Metastatic

Abstract 1260MO: Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. G Giaccone…RE Sanborn et al.

Presented September 18 and available on demand.

ePoster Sessions

Trials in Progress

Abstract 976TiP: SPEARHEAD-2 trial design: A Phase 2 pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer (r/m HNSCC). Cohen E, Dunn L, Neupane P, Gibson M, Leidner R, Savvides P, Hyland N, Trivedi T, Dudley M, Biswas S, Williams D, Norry E.

Abstract 1074TiP: SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies. E. Garralda, R.E. Sanborn, A.R. Minchom, D. Davar, G. Curigliano, V. Ribrag, A. Mehta, F. Foss, P. Garfin, S. Ansell.

Presented September 17 and available on demand.

Follow us on Twitter and Facebook for the latest news, articles and more. To learn more about our comprehensive care for patients with lung and head and neck cancers, visit Providence Thoracic Oncology Program and Providence Head and Neck Cancer Program.

A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.
Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.
SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.
Providence Cancer Institute lung cancer expert to present a virtual education talk on lung cancer screening, prevention and latest treatments.